Pluripotent stem cell (PSC)

Pluripotent stem cells (PSCs) are a unique class of cells characterized by the capacity for indefinite self-renewal and the potential to differentiate into any cell type derived from the three primary germ layers: ectoderm, endoderm, and mesoderm (NIH, 2016). This category primarily includes embryonic stem cells (ESCs), derived from the inner cell mass of a blastocyst, and induced pluripotent stem cells (iPSCs), which are adult somatic cells reprogrammed to a pluripotent state via the introduction of specific transcription factors such as OCT4, SOX2, KLF4, and c-MYC (Takahashi & Yamanaka, 2006). In a therapeutic context, PSCs are not traditional molecular targets like receptors or enzymes; rather, they serve as a foundational platform for regenerative medicine, disease modeling, and high-throughput drug toxicity screening (Cell Stem Cell, 2017). Their clinical application involves the transplantation of PSC-derived specialized cells to replace damaged or diseased tissues in conditions such as Parkinson's disease, macular degeneration, or myocardial infarction. However, significant safety challenges remain, most notably the risk of teratoma formation from residual undifferentiated cells and the potential for immunogenicity or the acquisition of deleterious genetic mutations during long-term culture (Science Translational Medicine, 2013).

Other names

Embryonic stem cellInduced pluripotent stem celliPSCESCUndifferentiated stem cellHuman pluripotent stem cell

Pluripotent stem cells are not a single molecular target; however, pharmacological agents modulate their state by inhibiting or activating specific signaling pathways (e.g., Wnt/beta-catenin, TGF-beta/Nodal, and MAPK/ERK) and epigenetic modifiers to maintain pluripotency, induce reprogramming, or drive directed differentiation into specific therapeutic cell lineages (Nature Reviews Molecular Cell Biology, 2011).